arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Zentalis Pharmaceuticals, Inc.

ZNTL

$4.22 ▼ -0.77 (-15.43%) at close

30 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Zentalis Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $296.5M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -20.8% ↘

FCF / Share $-0.47

Trailing P/E —

Price / Book 1.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-35.35M

↑ +26.8% —

Operating Margin Operating profit as % of sales

-185.6%

↓ -203.9% —

FCF / Share Free cash flow per share

$-0.47

↓ -3.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	25.4% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	25.8% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	33.9% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	70.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	20.5% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	29.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	33.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	9.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	17.7% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-38.1% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	18.3% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	18.6% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-966.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	-15.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	26.8% Excellent ↓ Excellent Declining Year-over-year change in net income	25.8% Excellent ↓ Excellent Declining Year-over-year change in net income	33.5% Excellent ↓ Excellent Declining Year-over-year change in net income	69.6% Excellent ↑ Excellent Improving Year-over-year change in net income	N/M	22.1% Good ↓ Good Declining Year-over-year change in net income	27.7% Excellent ↑ Excellent Improving Year-over-year change in net income	21.6% Good ↑ Good Improving Year-over-year change in net income	N/M	-10.8% Weak ↑ Weak Improving Year-over-year change in net income	-2.1% Weak ↑ Weak Improving Year-over-year change in net income	-64.6% Weak ↑ Weak Improving Year-over-year change in net income	-7.0% Weak ↑ Weak Improving Year-over-year change in net income	-9.8% Weak ↑ Weak Improving Year-over-year change in net income	-1198.0% Weak ↓ Weak Declining Year-over-year change in net income	-25.3% Weak ↓ Weak Declining Year-over-year change in net income	-18.4% Weak ↓ Weak Declining Year-over-year change in net income	-24.2% Weak ↑ Weak Improving Year-over-year change in net income	87.9% Excellent ↑ Excellent Improving Year-over-year change in net income	-103.2% Weak ↑ Weak Improving Year-over-year change in net income	-209.4% Weak ↓ Weak Declining Year-over-year change in net income	-177.8% Weak ↓ Weak Declining Year-over-year change in net income	-179.9% Weak ↓ Weak Declining Year-over-year change in net income	-156.5% Weak Weak Year-over-year change in net income	-93.3% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-3.1% Weak Weak Year-over-year change in free cash flow	—	—	—	37.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	11.8% Fair Fair Year-over-year change in free cash flow	—	—	—	25.7% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-185.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1337%)	—	—	-61.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-507%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	-0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	0.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	6.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	—	-176.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1573%)	—	—	24.8% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+107%)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	—	—	—	—	—	-147.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-128.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.29x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	-5.17x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.76x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.70x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.08x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-20.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-15.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-11.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-4.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	—	-10.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-15.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	—	-12.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-13.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-18.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	—	-15.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-18.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—	—	—	—
Return on Capital (%) (%)	-15.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.9% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-11.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-4.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-10.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-10.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-14.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-14.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-8.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-10.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-18.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-19.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-229%)	-16.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-10.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-9.8% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-165%)	-16.3% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	-14.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-194%)	-11.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-176%)	-23.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-254%)	2.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-85%)	—	-11.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-177%)	-21.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-16.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-209%)	—	-12.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-185%)	-14.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	-18.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-225%)	—	-1.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-107%)	-24.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-263%)	-18.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-224%)	—	—	—	—	—	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Net Debt (USD)	$-31.93M	$-35.99M	$-39.07M	$-37.60M	$-41.93M	$-33.90M	$-41.32M	$-36.98M	$-37.62M	$-28.04M	$-110.75M	$-266.56M	$-36.28M	$-43.07M	$-42.55M	$-55.14M	$-30.57M	$-59.71M	$-40.81M	$-49.17M	$-29.00M	$-54.95M	$-92.55M	$-96.02M	$-63.65M	$-67.25M	$-80.53M	$-8.74M	$-16.11M	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Revenue per Share (USD)	—	—	$0.00	$0.00	$0.00	—	$0.00	$0.00	$0.57	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.50	$-0.49	$-0.37	$-0.37	$-0.67	$-0.66	$-0.56	$-1.24	$0.14	$-0.83	$-0.79	$-1.85	$-1.07	$-0.92	$-0.96	$-1.34	$-1.31	$-1.13	$-0.09	$-1.34	—	$-0.98	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.47	—	$-0.37	$-0.48	$-0.46	—	—	—	$-0.73	—	—	—	$-0.83	—	—	—	$-1.12	—	—	—	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$2.57	$3.13	$3.50	$3.81	$4.11	$4.73	$4.98	$5.38	$6.46	—	$6.82	$7.41	$6.49	—	$7.52	$8.29	$6.92	—	$8.70	$5.42	$6.54	—	—	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$2.57	$3.13	$3.50	$3.81	$4.11	$4.73	$4.93	$5.33	$6.41	—	$6.77	$7.36	$6.42	—	$7.45	$8.23	$6.83	—	$8.62	$5.33	$6.45	—	—	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	70.26M	—	72.14M	71.99M	71.68M	—	71.11M	71.04M	70.90M	—	70.61M	60.79M	59.28M	—	56.81M	51.12M	45.24M	—	44.61M	40.74M	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$182.86M	$216.63M	$251.13M	$272.57M	$293.45M	$333.34M	$345.39M	$372.92M	$449.01M	—	$469.35M	$512.17M	$353.87M	—	$379.83M	$418.99M	$257.80M	—	$338.15M	$225.87M	$273.56M	—	$348.83M	$222.91M	$49.07M	—	—	—	—	—
Total Equity (USD)	$182.68M	$216.20M	$252.87M	$274.50M	$295.38M	$337.19M	$354.33M	$382.58M	$458.77M	—	$481.77M	$523.14M	$385.49M	—	$428.50M	$472.49M	$315.30M	—	$393.43M	$223.84M	$268.39M	—	—	—	—	—	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗	Q3 FY2020 Sep 30, 2020 10-Q ↗	Q2 FY2020 Jun 30, 2020 10-Q ↗	Q1 FY2020 Mar 31, 2020 10-Q ↗	Q4 FY2019 Dec 31, 2019 10-K ↗	Q3 FY2019 Sep 30, 2019 10-Q ↗	Q2 FY2019 Jun 30, 2019 10-Q ↗	Q1 FY2019 Mar 31, 2019 10-Q ↗	Q4 FY2017 Dec 31, 2017 10-K ↗
Sales/Revenue/Turnover (USD)	—	$0.00	$0.00	$0.00	$0.00	$26.86M	$0.00	$0.00	$40.56M	$0.00	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Depreciation Expense (USD)	$151.00K	$157.00K	$160.00K	$160.00K	$262.00K	$317.00K	$321.00K	$327.00K	$324.00K	$337.00K	$348.00K	$344.00K	$360.00K	$359.00K	$375.00K	$348.00K	$344.00K	$209.00K	$137.00K	$119.00K	$79.00K	$33.00K	$51.00K	$38.00K	$38.00K	$41.00K	$25.00K	$24.00K	$21.00K	—
Net Income, GAAP (USD)	$-35.35M	$-35.22M	$-26.69M	$-26.87M	$-48.28M	$-47.47M	$-40.16M	$-88.28M	$10.07M	$-60.92M	$-55.53M	$-112.53M	$-63.22M	$-54.97M	$-54.40M	$-68.36M	$-59.08M	$-50.06M	$-4.19M	$-54.57M	$-49.90M	$-40.30M	$-34.55M	$-26.86M	$-16.13M	$-14.51M	$-12.34M	$-10.47M	$-8.34M	—
Operating Cash Flow (USD)	$-32.96M	$-30.94M	$-26.96M	$-34.71M	$-32.64M	$-39.70M	—	—	$-51.97M	$-40.60M	—	—	$-49.28M	$-37.33M	—	—	$-50.20M	$-37.02M	—	—	$-37.47M	$-27.36M	—	—	$-16.87M	$-13.19M	$-9.99M	$-6.96M	$-9.01M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters

Zentalis Pharmaceuticals, Inc.

Analytical Summary

30-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ZNTL with peers